ASCO-GU – Arcus goes it alone in HIF2α
Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.
Merck gets saci in ovarian
Sacituzumab tirumotecan joins raludotatug deruxtecan on the ovarian cancer pivotal stage.
Xilio's second bailout
AbbVie follows Gilead in throwing Xilio a lifeline.
Pivotal study designs revealed
Keenly awaited trials of ficerafusp alfa, Trodelvy and divarasib materialise.
ASCO-GI – no masking Xilio's setback
Poor efficacy clouds prospects for the company's "improved" Yervoy.
Gilead and Galapagos's conscious uncoupling
Galapagos distances itself from Gilead, and offers a pure-play oncology cell therapy focus.
More bad vibes kill off Merck’s TIGIT and Lag3
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
ASH 2024 – Arcellx is happy to share in Car-T
Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.
